WHR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3779698	0.67	7/20
Hydrochloric Acid (SCHEMBL3639996)	0.66	7/20
SCHEMBL2170933	0.50	5/20
SCHEMBL10036161	0.43	5/20
Trifluoroacetic Acid (SCHEMBL4965758)	0.52	4/20
SCHEMBL3318248	0.52	4/20
SCHEMBL3319202	0.51	4/20
SCHEMBL3319575	0.51	4/20
Trifluoroacetic Acid (SCHEMBL4969262)	0.49	4/20
SCHEMBL4524523	0.46	4/20
Trifluoroacetic Acid (SCHEMBL2831633)	0.36	4/20
SCHEMBL2914245	0.58	3/20
SCHEMBL2923197	0.53	3/20
SCHEMBL8076201	0.52	3/20
SCHEMBL2170706	0.51	3/20
SCHEMBL8070274	0.50	3/20
SCHEMBL8070244	0.49	3/20
SCHEMBL2170980	0.48	3/20
SCHEMBL2170380	0.47	3/20
SCHEMBL3635656	0.47	3/20

Clinical trials — most relevant to WHR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss	PHASE1/PHASE2	COMPLETED
Satraplatin and Prednisone to Treat Prostate Cancer	PHASE2	COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC	EARLY_PHASE1	RECRUITING
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions	nan	COMPLETED
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science	nan	RECRUITING
Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal	nan	COMPLETED
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families	nan	RECRUITING
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan	nan	ENROLLING_BY_INVITATION
Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia	nan	COMPLETED
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia	nan	UNKNOWN
Identification of Genetic Factors Implicated in Orofacial Cleft Using Whole Exome Sequencing	nan	RECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome	nan	WITHDRAWN
Genetic Study of Age-Related Macular Degeneration	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy	nan	COMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes	nan	ACTIVE_NOT_RECRUITING
Chordoma Family Study	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a WHR1 binder may also engage these)

Protein	Name	Similarity
Q9JHN8	—	1.000	Q9JHN8 →
A0A1L8F8I9	—	0.983	A0A1L8F8I9 →
Q6PGY6	—	0.977	Q6PGY6 →
Q9ESJ4	—	0.976	Q9ESJ4 →
Q96RY7	—	0.976	Q96RY7 →
Q14AI0	—	0.976	Q14AI0 →
Q8VZC9	—	0.976	Q8VZC9 →
CPSF1	Cleavage and polyadenylation specificity factor subunit 1	0.976	landscape →
Q10QS7	—	0.975	Q10QS7 →
A2CEI4	—	0.975	A2CEI4 →
Q9NZQ3	—	0.975	Q9NZQ3 →
Q8IV36	—	0.975	Q8IV36 →
A7E2V1	—	0.974	A7E2V1 →
Q08DK0	—	0.974	Q08DK0 →
A0AVI4	—	0.974	A0AVI4 →
Q9EPU4	—	0.974	Q9EPU4 →
Q8K304	—	0.974	Q8K304 →
A1A4I9	—	0.974	A1A4I9 →
B2GV24	—	0.974	B2GV24 →
Q7ZYP6	—	0.974	Q7ZYP6 →
Q38899	—	0.974	Q38899 →
UFL1	E3 UFM1-protein ligase 1	0.974	landscape →
NAT10	RNA cytidine acetyltransferase	0.973	landscape →
P0CI65	—	0.973	P0CI65 →
Q4QQS8	—	0.973	Q4QQS8 →
Q7TQK1	—	0.973	Q7TQK1 →
Q28DV7	—	0.973	Q28DV7 →
Q8CCJ3	—	0.973	Q8CCJ3 →
Q8R4H7	—	0.973	Q8R4H7 →
Q5ZL91	—	0.973	Q5ZL91 →